Recorlev (Levoketoconazole) Patent Expiration, LOE Window & CMS Spending
Recorlev (Levoketoconazole) by Strongbridge Dublin: FDA Orange Book LOE 2040-03-02, 0 AB generics, $39.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Strongbridge Dublin |
| FDA Application & Pathway | N214133 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2040-03-02 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $39.8M |
| 2024 Medicare Part D Spend | $29.7M |
| 2024 Medicaid Spend | $10.2M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 38.7% 2-yr change) |